BAFF is increased in renal transplant patients following treatment with alemtuzumab
about
Biologics in organ transplantationTransplantation tolerance and its outcome during infections and inflammationElevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejectionPrevention trumps treatment of antibody-mediated transplant rejectionNeutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model.The role of B cells in solid organ transplantation.The generation and maintenance of serum alloantibody.B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation.Diagnosis and management of antibody-mediated rejection: current status and novel approaches.p52 Activation in monomorphic B-cell posttransplant lymphoproliferative disorder/diffuse large B-cell lymphoma without BAFF-R expressionLongitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.Tolerogenic therapies in transplantation.Clinical Significance of Pre- and Post-Transplant BAFF Levels in Kidney Transplant Recipients.B Cells, Antibodies, and More.Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients.Regulatory T Cell Infusion Can Enhance Memory T Cell and Alloantibody Responses in Lymphodepleted Nonhuman Primate Heart Allograft RecipientsCostimulation blockade alters germinal center responses and prevents antibody-mediated rejection.Tolerance in clinical transplantation: progress, challenge or just a dream?Monitoring tolerance and rejection in organ transplant recipients.Lymphodepletion and homeostatic proliferation: implications for transplantation.Induction therapy in renal transplant recipients: how convincing is the current evidence?B cells and antibodies in multiple sclerosis pathogenesis and therapy.Lymphodepletional strategies in transplantation.Recollective homeostasis and the immune consequences of peritransplant depletional induction therapy.Advances in pharmacotherapy to treat kidney transplant rejection.Targeting the Monocyte-Macrophage Lineage in Solid Organ TransplantationB Cell Immunity in Solid Organ Transplantation.Preemptive CD20+ B cell Depletion Attenuates Cardiac Allograft Vasculopathy in CD154-Treated Monkeys.B-cell tolerance in transplantation: is repertoire remodeling the answer?B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naïve B cells.Delayed allograft inflammation following alemtuzumab induction for kidney transplantation.Elevated serum levels of B-cell activating factor in pediatric renal transplant patients.Blockade of BAFF Receptor BR3 on T Cells Enhances Their Activation and Cytotoxicity.Soluble BAFF Cytokine Levels and Antibody-Mediated Rejection of the Kidney Allograft.An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation.The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.Proteasome Inhibitor Carfilzomib-Based Therapy for Antibody-Mediated Rejection of the Pulmonary Allograft: Use and Short-Term Findings.Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody.IL-21 Biased Alemtuzumab Induced Chronic Antibody-Mediated Rejection Is Reversed by LFA-1 Costimulation Blockade
P2860
Q26829578-3221E7A5-B716-4F9A-B883-585E698299DDQ26829817-F54AC657-1EA0-4B9E-8829-A83C687978ABQ28294329-475DD0A6-6038-4F4B-BF1F-5480356CBCA2Q33755462-E673C9BF-32A2-4D25-A609-89C6FDAAFA43Q33891669-376A9848-21B9-4CFF-B10A-77EEBE6B3C64Q33891696-6B3322D7-355F-4DC9-A6C9-8F219CC0A9D3Q34106158-9B483955-E425-4EAA-B244-9FCBF2C26047Q34159016-AFB13449-42CF-49F6-92DA-6BDD4F757FE6Q34841849-A732DB9C-E21A-46ED-A171-6E98DBB62C1BQ35235728-C9C8EE08-F8F9-41AD-AD02-8E565B968801Q35418255-070302D8-A4D6-4DDB-BB44-B36E8A50BA2CQ36102133-351976A6-796E-4D66-919B-AB2DF77684A0Q36134073-C88C88CF-DC6E-47B4-847E-1A4CB0C1C81FQ36432935-E11ED1EB-ED76-4104-9BBA-0A16E6C297DDQ36769110-D0FB4B89-A16D-4C0B-A281-1F883EA67743Q37033965-C6D80593-E2FC-4DA4-BC08-735F7D67FD41Q37700827-7233610A-3D24-4FA6-9F27-2F0113F0D525Q37854490-831D4DD0-57B0-454E-AC70-170F675E0AD2Q37894733-8999FC79-ED7F-4D71-8406-59D7B7E4E3C9Q37993873-3D2E368E-C17E-409F-9746-339F02F256C5Q37996078-C50152B3-C054-44BE-A99C-00185149EE48Q38050398-67A43DE6-148F-4D45-8FE6-89F36D2F701DQ38118743-09178134-69A0-4B1B-8DEB-08228C11B522Q38187176-774580AC-81C8-4811-B4C3-91E8164E19BAQ38544529-DF242693-281A-452C-8553-16BD16B27356Q38750505-DE786BE1-A205-42C5-88CF-7936C958EA6BQ39101892-DB342F82-08CA-4CE2-9C6F-EE09C81526E2Q40630490-A307A858-CCAE-4E07-9122-3BD575C7D15AQ42038591-161283EC-F184-4EF3-8729-1D44BE2F4BA3Q42221525-038680C8-C2DA-4C50-83F8-66CADDCC02D9Q44433786-683DC980-FE47-492C-9DC6-A9D5B4FAF53AQ45444391-34F251CC-3E37-4C16-B02B-C5693D613DA8Q47198559-347A5F65-C425-48E1-A662-438F264DAD6AQ50955240-F04A08E8-B897-4340-B172-7C81BB2E9E68Q50963419-159BFE8C-A143-4844-AE08-41DA66A7528EQ51010023-FE87A13C-D0F1-42E9-A635-C8174536B01EQ52793674-2BECD326-F129-44F0-8831-565B5BBDF171Q53459320-D86C3133-0A91-42C5-B6C1-4B71B688BF7CQ58122073-3278486B-D363-4EAC-BF4A-5DE71D5FB3B8
P2860
BAFF is increased in renal transplant patients following treatment with alemtuzumab
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
BAFF is increased in renal transplant patients following treatment with alemtuzumab
@en
type
label
BAFF is increased in renal transplant patients following treatment with alemtuzumab
@en
prefLabel
BAFF is increased in renal transplant patients following treatment with alemtuzumab
@en
P2093
P2860
P1476
BAFF is increased in renal transplant patients following treatment with alemtuzumab
@en
P2093
M Samaniego
S Knechtle
P2860
P304
P356
10.1111/J.1600-6143.2009.02710.X
P407
P577
2009-06-12T00:00:00Z